第三代心臟輔助系統可以作為心臟衰竭患者心臟移植的永久替代治療方式。

VentrAssist系統是由Ventracor公司(Chatswood, NSW, Australia)生產的，是第三代左心室輔助設備(LVAD)，用于治療心臟衰竭患者以提高生活質量。同時該系統還可以作為心臟移植的橋梁，還可能是通向康復的橋梁，從而給病變心臟一個恢復的機會。CE標記臨床試驗已經完成，投放歐洲市場的各項準備正在進行之中。

 
By medinews.com staff writers
 
A third-generation cardiac-assist system has been designed as a permanent alternative to a heart transplant for patients suffering from heart failure.

The VentrAssist system, manufactured by Ventracor (Chatswood, NSW, Australia), is a third-generation left-ventricle-assist device (LVAD) system designed to provide patients suffering from heart failure with better quality of life. It can also be used as a bridge to heart transplant and possibly as a bridge to recovery, where it may allow a deteriorating heart an opportunity to recuperate. The CE Mark trial has been completed, and preparations are underway for a European market launch.